New Report from AIS and Advera Health Analyzes Adverse Effects of Anti-Inflammatory Drugs

Share Article

The Cost and Impact of Adverse Events: Anti-Inflammatory Drugs, the new first-in-a-series report from Advera Health Analytics, Inc. and Atlantic Information Services, provides actionable data that will help payers and P&T committees achieve cost savings and value in formulary and coverage decisions.

With data on adverse drug events from Advera Health Analytics, Inc. (fka AdverseEvents) and on drug benefit designs from Atlantic Information Services, Inc. (AIS), The Cost and Impact of Adverse Events: Anti-Inflammatory Drugs provides data on the post-market experiences of patients taking the anti-inflammatory medications Cimzia, Enbrel, Humira, Otezla, Remicade, Simponi and Stelara. The report is the first in a new series from Advera Health and AIS.

Published independently from drug manufacturers, the report’s charts and tables identify safety risks to help payers and pharmacy and therapeutic (P&T) committees refine formulary strategies and protocols for greater cost savings and better outcomes. A concluding summary highlights areas where each product stands out for labeled adverse events, non-labeled adverse events, the most serious adverse events and the actual cost to payers of adverse events, as compared with other drugs available for the same indications.

By examining trusted data sources developed to help pharmacy benefit professionals obtain actionable data, The Cost and Impact of Adverse Events: Anti-Inflammatory Drugs focuses on two factors:

  • Adverse drug events, with a focus on the downstream costs to health plans that are incurred when a patient experiences a serious adverse event from a prescribed medication, provided by Advera Health, which specializes in redefining drug safety data. This report taps into AdverseEvents Explorer, the set of analytics Advera Health developed to alert payers to serious adverse drug reactions, and help them predict the downstream costs of those events and compare the long-term impact of various formulary strategies as applied to a single drug class.
  • Drug benefit designs (particularly in relation to out-of-pocket member costs) and their impact on access and adherence, from AIS’s Rx Benefit Data, a new database that tracks prescription drug benefit offerings and plan design parameters of commercial health plans in a comparative format.

For more information on The Cost and Impact of Adverse Events: Anti-Inflammatory Drugs, including a full table of contents and a sample PDF containing the introduction and methodology, visit

About Advera Health
Advera Health Analytics, Inc. is a California-based healthcare informatics company that improves patient safety and reduces systemic health care costs through the comprehensive analysis of post-marketing drug side-effect data. Utilizing data-mining and analysis technology through its proprietary RxSuite of analytics, Advera Health makes post-marketing drug safety data accessible, actionable and predictable.

Advera Health provides services to enterprise markets including managed care organizations, the pharmaceutical industry and financial institutions, all while keeping the patient as the key stakeholder. For more information, visit

About AIS
Atlantic Information Services, Inc. (AIS) is a publishing and information company that has been serving the health care industry for more than 25 years. It develops highly targeted news, data and strategic information for managers in hospitals, health plans, medical group practices, pharmaceutical companies and other health care organizations. AIS products include print and electronic newsletters, websites, looseleafs, books, strategic reports, databases, webinars and conferences. Learn more at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Susan Namovicz-Peat, Director, Directories and Databases Division
Atlantic Information Services
+1 (202) 775-9008 Ext: 3045
Email >
Follow >
since: 01/2011
Like >
Atlantic Information Services, Inc.

Visit website